Drug major Intas Pharmaceuticals and IntegriMedical have partnered to introduce needle-free injection systems for in-vitro fertilization and gynecology therapies in India.The collaboration aims to streamline deployment of the technology nationwide.
Needle-Free Technology- The system delivers medication via a high-pressure jet stream,creating a consistent,spray-like pattern,reducing discomfort for patients.
IVF Market Growth- India’s IVF market is rapidly expanding, currently at 300,000-350,000 cycles annually, projected to reach 500,000-600,000 by 2027.
Patient Benefits- Companies state the technology will reduce injection-related anxiety and improve patient compliance,potentially benefiting thousands of women each year.
Launch Timeline- Intas targets an all-India launch in the first quarter of fiscal year 2026, begining with distribution to approximately 500 doctors.
Potential Costs- While U.S. prices range from $3,500 to $5,000, intas aims for substantially lower costs in India to encourage widespread adoption.
Market Exclusivity- Intas will be the first Indian company offering IVF and gynecology therapies with needle-free injection systems through this exclusive agreement.
